Pauline Jen Ryan
Corporate Officer/Principal at OCULAR THERAPEUTIX, INC.
Profile
Pauline Jen Ryan is currently the Head of Business and Corporate Development at Ocular Therapeutix, Inc. and a Partner at Red Sky Partners LLC.
She was previously the Chief Executive Officer at Verik Bio, Inc. from 2012 to 2017, the Senior Vice President of Corporate Development and Operations at ImmunoGen, Inc. from 1999 to 2007, and the Senior Vice President of Business Operations at Proteostasis Therapeutics, Inc. from 2007 to 2011.
She received her undergraduate degree from Northwestern University and her MBA from Kellogg School of Management.
Pauline Jen Ryan active positions
| Companies | Position | Start |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Corporate Officer/Principal | - |
| Red Sky Partners LLC | Corporate Officer/Principal | 2014-06-30 |
Former positions of Pauline Jen Ryan
| Companies | Position | End |
|---|---|---|
| Verik Bio, Inc. | Chief Executive Officer | 2017-10-31 |
| PROTEOSTASIS THERAPEUTICS, INC. | Corporate Officer/Principal | 2011-07-31 |
| IMMUNOGEN, INC. | Corporate Officer/Principal | 2007-07-25 |
Training of Pauline Jen Ryan
| Northwestern University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| Private companies | 4 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
| Red Sky Partners LLC | |
| Verik Bio, Inc. |
- Stock Market
- Insiders
- Pauline Jen Ryan
